In Silico Polypharmacological Profiling of Lupeol and 1-Heptatriacontanol from Probiotic Limosilactobacillus reuteri GM4 and Streptococcus equinus WC1 against Colorectal Cancer-Associated Targets

Abstract Cancer's molecular wiring is notoriously hard to untangle, so computational tools have become essential for mapping disease mechanisms and narrowing down therapeutic leads. Here, we applied in silico screening to evaluate the anticancer potential of metabolites from two probiotic gut isolates: Streptococcus equinus WC1 (SE-WC1) and Limosilactobacillus reuteri GM4 (LR-GM4). Lactic acid bacteria are core members of the human gut microbiota, and their metabolic repertoire—ranging from pathogen suppression to immune modulation and vitamin synthesis—has attracted growing scientific attention. GC–MS profiling of volatile hydrocarbons identified lupeol (14.49%) and 1-heptatriacontanol (5.48%) as the major bioactive constituents, with lupeol detectable in both strains at differing abundances. Docking simulations against ten cancer-linked proteins revealed that lupeol bound more strongly than 1-heptatriacontanol at eight out of ten targets. Its calculated free energies ran from − 6.2 kcal/mol (NR1I3) down to − 11.0 kcal/mol (HSD11B1), whereas 1-heptatriacontanol managed only − 3.2 kcal/mol (SHH) to − 6.8 kcal/mol (UGT2B7). The energy gap (ΔΔG) was smallest at GPBAR1 (− 0.4 kcal/mol) and largest at HSD11B1 (− 4.7 kcal/mol), with intermediate differences at AR (− 4.0), SHH (− 3.9), CDC25B (− 3.4), and TRPM8 (− 3.0 kcal/mol). Because lupeol successfully engaged structurally unrelated proteins—nuclear receptors, phosphatases, ion channels, and metabolic enzymes alike—its superior binding appears to stem from inherent scaffold properties rather than target-specific recognition.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-13
DOI
https://doi.org/10.21203/rs.3.rs-10913054/v1
Primary Topic
Computational Drug Discovery Methods
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

In Silico Polypharmacological Profiling of Lupeol and 1-Heptatriacontanol from Probiotic Limosilactobacillus reuteri GM4 and Streptococcus equinus WC1 against Colorectal Cancer-Associated Targets

Mona A. Ashour, Metwally Khaled
4 links
Research Square
Computational Drug Discovery Methods
preprint

In Silico Polypharmacological Profiling of Lupeol and 1-Heptatriacontanol from Probiotic Limosilactobacillus reuteri GM4 and Streptococcus equinus WC1 against Colorectal Cancer-Associated Targets

Mona A. Ashour, Metwally Khaled
preprint en

Abstract

Abstract Cancer's molecular wiring is notoriously hard to untangle, so computational tools have become essential for mapping disease mechanisms and narrowing down therapeutic leads. Here, we applied in silico screening to evaluate the anticancer potential of metabolites from two probiotic gut isolates: Streptococcus equinus WC1 (SE-WC1) and Limosilactobacillus reuteri GM4 (LR-GM4). Lactic acid bacteria are core members of the human gut microbiota, and their metabolic repertoire—ranging from pathogen suppression to immune modulation and vitamin synthesis—has attracted growing scientific attention. GC–MS profiling of volatile hydrocarbons identified lupeol (14.49%) and 1-heptatriacontanol (5.48%) as the major bioactive constituents, with lupeol detectable in both strains at differing abundances. Docking simulations against ten cancer-linked proteins revealed that lupeol bound more strongly than 1-heptatriacontanol at eight out of ten targets. Its calculated free energies ran from − 6.2 kcal/mol (NR1I3) down to − 11.0 kcal/mol (HSD11B1), whereas 1-heptatriacontanol managed only − 3.2 kcal/mol (SHH) to − 6.8 kcal/mol (UGT2B7). The energy gap (ΔΔG) was smallest at GPBAR1 (− 0.4 kcal/mol) and largest at HSD11B1 (− 4.7 kcal/mol), with intermediate differences at AR (− 4.0), SHH (− 3.9), CDC25B (− 3.4), and TRPM8 (− 3.0 kcal/mol). Because lupeol successfully engaged structurally unrelated proteins—nuclear receptors, phosphatases, ion channels, and metabolic enzymes alike—its superior binding appears to stem from inherent scaffold properties rather than target-specific recognition.

Research Square
Ain Shams University (EG)
Good health and well-being
Computational Drug Discovery Methods
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon